[{"orgOrder":0,"company":"GreenLight Clinical","sponsor":"Epygenix Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Clemizole hydrochloride","moa":"H1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"GreenLight Clinical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"GreenLight Clinical \/ GreenLight Clinical","highestDevelopmentStatusID":"8","companyTruncated":"GreenLight Clinical \/ GreenLight Clinical"}]

Find Clinical Drug Pipeline Developments & Deals by GreenLight Clinical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BioFlorida Conference
                          Not Confirmed
                          BioFlorida Conference
                          Not Confirmed

                          Details : This Phase 2 study will confirm the efficacy and safety of EPX-100 with children suffering from Dravet Syndrome. The Company is now recruiting patients for this clinical study, collaborated with GreenLight Clinical.

                          Brand Name : EPX-100

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 17, 2020

                          Lead Product(s) : Clemizole hydrochloride

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Recipient : Epygenix Therapeutics

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank